Depression and Leukocyte Telomere Length in Patients With Coronary Heart Disease:Data From The Heart and Soul Study by Hoen, Petra W. et al.
  
 University of Groningen
Depression and Leukocyte Telomere Length in Patients With Coronary Heart Disease
Hoen, Petra W.; de Jonge, Peter; Na, Bee Ya; Farzaneh-Far, Ramin; Epel, Elissa; Lin, Jue;





IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date:
2011
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Hoen, P. W., de Jonge, P., Na, B. Y., Farzaneh-Far, R., Epel, E., Lin, J., ... Whooley, M. A. (2011).
Depression and Leukocyte Telomere Length in Patients With Coronary Heart Disease: Data From The
Heart and Soul Study. Psychosomatic Medicine, 73(7), 541-547.
https://doi.org/10.1097/PSY.0b013e31821b1f6e
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the
number of authors shown on this cover page is limited to 10 maximum.
Download date: 12-11-2019
Depression and Leukocyte Telomere Length in Patients With Coronary
Heart Disease: Data From The Heart and Soul Study
PETRA W. HOEN, BSC, PETER DE JONGE, PHD, BEE YA NA, MPH, RAMIN FARZANEH-FAR, MD, ELISSA EPEL, PHD, JUE LIN, PHD,
ELIZABETH BLACKBURN, PHD, AND MARY A. WHOOLEY, MD
Objective: Shortened telomere length has been associated with mortality in patients with coronary heart disease (CHD) and is
considered as an emerging marker of biologic age. Whether depression is associated with telomere length or trajectory has not been
evaluated in patients with CHD. Methods: In a prospective cohort study, we measured leukocyte telomere length in 952 participants
with stable CHD at baseline and in 608 of these participants after 5 years of follow-up. The presence of major depressive disorder in the
past month was assessed using the computerized diagnostic interview schedule at baseline. We used linear and logistic regression
models to evaluate the association of depression with baseline and 5-year change in leukocyte telomere length. Results: Of the 952
participants, 206 (22%) had major depression at baseline. After the adjustment for age and sex, the patients with current major
depressive disorder had shorter baseline telomere length than those without depression (mean [standard error] = 0.86 [0.02] versus 0.90
[0.01]; p = .02). This association was similar (but no longer statistically signiﬁcant) after adjustment for body mass index, smoking,
diabetes, left ventricular ejection fraction, statin use, antidepressant use, physical inactivity, and anxiety (0.85 [0.02] versus 0.89 [0.01],
p = .06). Depression was not predictive of 5-year change in telomere length after adjustment for the mentioned covariates and base-
line telomere length. Conclusions: Depression is associated with reduced leukocyte telomere length in patients with CHD but does
not predict 5-year change in telomere length. Future research is necessary to elucidate the potential mechanisms underlying the
association between depression and telomere length. Key words: depression, telomere length, stable CHD.
CHD = coronary heart disease; MDD = major depressive disorder;
CDIS-IV = computerized diagnostic interview schedule; MI =
myocardial infarction; PHQ = Patient Health Questionnaire; BMI =
body mass index; LVEF = left ventricular ejection fraction.
INTRODUCTION
Telomeres are specialized tandem deoxyribonucleic acid(DNA) repeat sequences (TTAGGG)n located at the ends
of eukaryotic chromosomes, which protect somatic cells from
genomic instability during mitotic cell proliferation (1). During
mitosis, the telomere is not fully replicated because of the
inherent properties of DNA polymerase, resulting in obligate
telomere shortening with each cell division. Eventually, telo-
mere shortening can result in cessation of mitosis (senescence)
or programmed cell death (apoptosis) (2). Thus, telomere attri-
tion has been proposed as the basis for a ‘biologic clock’ that
integrates the cumulative effect of environmental stressors inde-
pendently of chronological age (3).
Since the discovery of telomeres, there is a growing body
of literature linking shortened telomeres with increased age-
related morbidity and mortality. Previous studies have found
that psychological distress is associated with short telomere
length in otherwise healthy adults (4Y6) and in older patients
with heart failure (7). However, the association between de-
pression and telomere length has not been evaluated in patients
with coronary heart disease (CHD). Furthermore, the effect of
depression on subsequent change in telomere length over time
has not been examined in any patient population. Evaluating
this effect is of importance for our understanding of human
telomere biology over time in depressed patients.
Both depression and short telomere length predict mortality
in patients with CHD (8Y11). Whether depression is associated
with leukocyte telomere length or telomere trajectory among
patients with stable CHD is unknown. We sought to investigate
the association among depression, telomere length, and telo-
mere trajectory in a prospective cohort study of patients with
stable CHD. In addition, we evaluated whether differences in
leukocyte telomere length might contribute to the adverse
cardiovascular outcomes associated with depressive symptoms.
METHODS
Design and Participants
The Heart and Soul Study is a prospective cohort study focused on psy-
chosocial factors and health outcomes in patients with stable CHD. Details
regarding the study design have been described previously (12). Between
September 2000 and December 2002, 1024 patients were recruited from 12
outpatient clinics in San Francisco Bay Area. Inclusion criteria were history of
myocardial infarction (MI) or coronary revascularization, angiographic evi-
dence of at least 50% stenosis in at least one coronary vessel, or a diagnosis of
CHD by an internist or cardiologist. Patients were excluded if they had a history
of MI in the past 6 months, were unable to walk one block, or were planning to
move out of the local area within 3 years. Patients underwent a baseline study
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examination that included a comprehensive health interview, blood samples,
medical history, questionnaire, psychosocial questionnaire, and exercise tread-
mill test with stress echocardiography. Of the 1024 enrolled patients, 954
provided DNA samples for the analysis at baseline, and 608 of these partici-
pants provided DNA samples again after 5 years of follow-up (13). The study
protocol was approved by the appropriate institutional review boards, and all
participants signed an informed consent.
Assessment of Depression
We ascertained the presence of major depressive disorder (MDD) in the past
month according to Diagnostic and Statistical Manual, Fourth Edition, criteria.
We used the modiﬁed Computerized National Institute of Mental Health Di-
agnostic Interview Schedule (CDIS-IV), a highly structured interview designed
to yield psychiatric diagnosis (14). The CDIS-IV is a validated computerized
version of the health care professionalYadministered, structured clinical inter-
view for the diagnosis of psychiatric illness. Trained research assistants ad-
ministered the interview during the daylong study appointment. We also
assessed the presence and severity of depressive symptoms using the nine-item
Patient Health Questionnaire (PHQ-9) (15). The PHQ-9 is a self-report
checklist derived from the Primary Care Evaluation of Mental Disorders in-
terview (16). The PHQ-9 measures the presence of depressive symptoms during
the previous 2 weeks (0 = not at all, 1 = several days, 2 = more than half the
days, and 3 = nearly everyday). We evaluated PHQ as a continuous variable
(range = 0Y27).
Telomere Length Assay
Details regarding telomere length assay in The Heart and Soul Study have
been described previously (13). Telomere length measurements were performed
in a blinded fashion without the knowledge of depression status. According to
standard procedures, genomic DNA was isolated from the peripheral blood
leukocytes that were stored at j70-C. Puriﬁed DNA samples were diluted in
96-well microtiter source plates to a ﬁxed concentration of 3 ng/KL. A quan-
titative polymerase chain reactionYbased assay was used to measure the relative
mean telomere length. This assay compares the mean telomere repeat sequence
copy number (T ) to a reference single copy gene copy number (S ) in each
sample. Standard curves were derived from serially diluted reference DNA. The
T/S ratio was calculated from the average quantity of the reference DNA found
to match with each experimental sample for the copy number of the targeted
template (for T: the number of telomere repeats, and for S: the number of
A-globin gene copies). The equation for conversion from T/S ratio to base pairs
for this study was base pairs = 3274 + 2413  (T/S) (13). The inter-assay
coefﬁcient of variability for telomere length measurement was 3.7%, and the
intra-assay coefﬁcient of variability was 2.5%.
Other Baseline Characteristics
Age, sex, ethnicity, education, smoking status, and alcohol use were de-
termined by the questionnaire. Weight and height were measured, and body
mass index (BMI, kg/m2) was calculated. Comorbid conditions were deter-
mined by self-report and included hypertension, MI, congestive heart failure,
and diabetes mellitus. Anxiety was assessed with the Hospital Anxiety and
Depression Scale. We assessed left ventricular ejection fraction (LVEF) using a
resting echocardiography. Resting systolic and diastolic blood pressure was
measured manually using a standard sphygmomanometer. To assess physical
activity, we asked, ‘‘Which of the following statements best describes how
physically active you have been during the last month, that is, done activities
such as 15 to 20 minutes of brisk walking, swimming, general conditioning, or
recreational sports?’’ The participants chose from one of the following six
categories: not at all active, a little active (1Y2 times per month), fairly active
(3Y4 times per month), quite active (1Y2 times per week), very active (3Y4 times
per week), or extremely active (Q5 times per week). Self-report has been shown
to be a reliable, valid, and accurate method of assessing physical activity
(17,18). The participants who reported that they were not at all or a little active
were considered physically inactive. Low- and high-density lipoprotein cho-
lesterol levels were determined from fasting venous blood samples. The parti-
cipants were instructed to bring their medication bottles to their appointment,
and study personnel recorded all current medications, including dose and fre-
quency use.
Heart Failure and Death
To determine whether differences in leukocyte telomere length might con-
tribute to the adverse cardiovascular outcomes associated with depressive
symptoms, we evaluated the association of depressive symptoms with mortality
before and after the adjustment for baseline telomere length. Annual telephone
interviews were conducted with participants or their proxies asking about
emergency department visits, hospitalizations, or death. For any reported event,
medical records, death certiﬁcates, and coroner’s reports were reviewed by two
independent blinded adjudicators. In the event of disagreement, a third blinded
adjudicator reviewed the event and determined the outcome variable. To be
diagnosed with heart failure, patients had to be hospitalized for a clinical
syndrome involving an acute change in at least two of the following: parox-
ysmal nocturnal dyspnea, orthopnea, elevated jugular venous pressure, pul-
monary rales, third heart sound, cardiomegaly, or pulmonary edema on chest
radiography. Death was conﬁrmed by review of death certiﬁcates.
Statistical Analyses
For descriptive purposes, the participants were grouped based on the
presence or absence of current major depression (by CDIS-IV) and compared
on clinical and demographic variables, using t tests and W2 tests. Telomere
length was normally distributed. For primary analyses, the association between
depression and mean telomere length at baseline was examined using gener-
alized linear models (for telomere length as a continuous variable) and logistic
regression for short telomere length, deﬁned a priori as having leukocyte
telomere length in Quartile 1 versus 4.
Percent change in telomere length was calculated as [(follow-up T/S j
baseline T/S)  100] divided by baseline T/S. The association between de-
pression and the 5-year change in telomere length was assessed using gener-
alized linear models (for percent change in telomere length as a continuous
variable) and logistic regression models for predicting telomere shortening
(deﬁned a priori as a 910% decrease in telomere length) versus maintained
(T10% change in telomere length) or lengthened (910% increase in telomere
length) (13). For multivariable models, the following covariates were chosen
based on cross-sectional associations with telomere length and depression: age,
sex, diabetes, BMI, smoking, LVEF, statin use, antidepressant use, physical
inactivity, and anxiety (9). To determine whether the effect of depression on
telomere trajectory differed in patients with shorter or longer baseline telomere
length, we tested an interaction term (depression by baseline telomere length) as
a predictor of shortening.
We have previously reported that depressive symptoms, but not MDD,
predict subsequent heart failure and death in The Heart and Soul Study (19). To
evaluate whether telomere length may be a mediator in this association, we
estimated the association of depressive symptoms with heart failure or death
using Cox proportional hazard models, with and without the adjustment for
baseline telomere length. Statistical analyses were performed using SAS soft-
ware version 9.1 (SAS Institute Inc, Cary, North Carolina).
RESULTS
Of the 954 patients who provided DNA samples for the
analysis at baseline, two had no CDIS measurement, leaving
952 patients to be included in further analyses. The baseline
characteristics of the study population categorized by current
depression are presented in Table 1. Of the 952 patients, 206
(22%) participants had current (past month) depression. Com-
pared with participants who did not have depression, those with
depression were younger and less likely to be male. They were
more likely to have higher LVEF, to smoke, to have diabetes
mellitus, to have a higher anxiety score, to use antidepressants,
and to be physically inactive, but less likely to use statins.
Depression and Baseline Telomere Length
After adjustment for age and sex, patients with current
MDD had shorter telomere length than patients without current
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depression (mean [standard error] = 0.86 [0.02] versus 0.90
[0.01], p = .02). This association was similar (but no longer
statistically signiﬁcant) after further adjustment for BMI,
smoking, diabetes, LVEF, statin use, antidepressant use, phys-
ical inactivity, and anxiety (0.85 [0.02] versus 0.89 [0.01], p =
.06; Table 2). The difference of 0.04 T/S units is comparable
with 97 base pairs. Compared with nondepressed participants,
those with major depression had a 71% greater odds of having
short telomere length (adjusted odds ratio = 1.71, 95% conﬁ-
dence interval [CI] = 0.98Y2.98, p = .06; Table 3). When entered
as a continuous variable, higher depressive symptom scores
were also associated with shorter telomere length, adjusted
for age, sex, diabetes, BMI, smoking, LVEF, and statin use
(A coefﬁcient =j0.00297, p = .03). Again, this association was
TABLE 2. Telomere Length (Analyzed as a Continuous Variable, Mean [Standard Error]) by the Presence of Major Depressive Disorder Among 952
Participants at Baseline
Adjusted for Current Depression (n = 206) No Current Depression (n = 746) p
Age and sex 0.86 (0.02) 0.90 (0.01) .02
Age, sex, diabetes, BMI, and smoking 0.86 (0.02) 0.89 (0.01) .04
Age, sex, diabetes, BMI, smoking, LVEF, statin use, physical inactivity,
and antidepressant use
0.85 (0.02) 0.89 (0.01) .04
Age, sex, diabetes, BMI, smoking, LVEF, statin use, physical inactivity,
antidepressant use, and anxiety
0.85 (0.02) 0.89 (0.01) .06
BMI = body mass index; LVEF = left ventricular ejection fraction.
TABLE 1. Baseline Characteristics of 952 Participants With Baseline Measurement of Telomere Length
Variable Current Depression (n = 206) No Current Depression (n = 746) p
Demographic characteristics
Age, y 61.7 (10.8) 68.1 (10.6) G.001
Male, n (%) 143 (69) 632 (85) G.001
White, n (%) 124 (60) 449 (60) .98
High school graduate, n (%) 182 (88) 646 (87) .56
Body mass index, kg/m2 29.01 (5.66) 28.31 (5.31) .10
Regular alcohol use, n (%) 60 (29) 216 (29) .98
Current smoking, n (%) 58 (28) 131 (18) G.001
Comorbid conditions
Hypertension, n (%) 146 (71) 526 (71) .96
Myocardial infarction, n (%) 100 (49) 408 (55) .13
Congestive heart failure, n (%) 37 (18) 126 (17) .72
Diabetes mellitus, n (%) 66 (32) 186 (25) .04
Anxiety score 8.90 (4.09) 4.45 (3.30) G.001
PHQ score 10.73 (5.58) 3.53 (4.12) G.001
Cardiac disease severity and risk factors
Resting left ventricular ejection fraction 0.63 (0.07) 0.61 (0.10) .005
Low-density lipoprotein cholesterol, mg/dL 107.54 (36.74) 103.31 (32.84) .12
High-density lipoprotein cholesterol, mg/dL 45.35 (14.84) 45.63 (13.93) .80
Systolic blood pressure 132.84 (21.90) 133.06 (20.93) .90
Diastolic blood pressure 75.26 (11.96) 74.43 (11.23) .36
Physical inactivity, n (%) 95 (45) 250 (34) .002
Medication use, n (%)
Aspirin 158 (77) 574 (77) .94
A blocker 114 (55) 433 (58) .49
Renin-angiotensin system inhibitor 102 (50) 386 (52) .57
Statin 119 (58) 492 (66) .03
Antidepressant use 99 (48) 78 (10) G.001
Data are presented as mean (SD) unless otherwise indicated.
SD = standard deviation; PHQ = Patient Health Questionnaire.
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no longer statistically signiﬁcant after further adjustment for
antidepressant use, physical inactivity, and anxiety (A coefﬁ-
cient = j0.00231, p = .17).
Depression and 5-Year Change in Telomere Length
Of the 1024 original enrollees, 195 had died before the
5-year examination, and 667 (80%) of the eligible 829 parti-
cipants completed the 5-year follow-up examination. Of the
667 participants who completed the 5-year examination, 59
were missing telomere length measurements at baseline and/or
follow-up, leaving 608 participants for the analysis of the 5-year
change. Compared with the 221 participants who were alive at
5 years but not included in the analyses, these 608 participants
had similar age and baseline telomere length. Overall, 276 par-
ticipants (45%) experienced telomere shortening, 192 (32%)
maintained their telomere length (T10%), and 140 experienced
telomere lengthening (23%). Compared with the 481 nonde-
pressed participants, the 127 participants with MDD at baseline
were less likely to experience telomere shortening (35% versus
48%) and more likely to experience telomere lengthening (26%
versus 21%; Fig. 1). After adjustment for age, sex, diabetes,
BMI, smoking, LVEF, statin use, antidepressant use, physical
inactivity, and anxiety, MDD was associated with a 32%
decreased odds of shortening. However, this association was
not signiﬁcant after further adjustment for shorter baseline telo-
mere length in the depressed participants (odds ratio = 0.76,
95% CI = 0.40Y1.44, p = .40; Table 4).
When the 5-year percent change in telomere length was
analyzed as a continuous variable, participants with MDD were
also less likely to experience telomere shortening than those
without depression (percent change = j0.9% [2.4%] versus
j6.6% [1.9%]; p = .03), adjusted for age, sex, diabetes, BMI,
smoking, LVEF, statin use, antidepressant use, physical inac-
tivity, and anxiety. Again, this association was no longer sig-
niﬁcant after adjustment for shorter baseline telomere length
in the depressed participants (percent change = j3.0% [1.7%]
versusj5.6% [1.3%]; p = .13; Table 5). We found no evidence
that the effect of depression on change in telomere length dif-
fered in patients with shorter or longer baseline telomere length
( p for interaction = .78).
Depressive Symptoms and Cardiovascular Outcomes
As of December 18, 2009, vital status was known for 949
(999%) of the 954 study participants, and there were 277
deaths. Each standard deviation (5.5-point) increase in PHQ
depressive symptom score was associated with a 16% increased
rate of death (age-adjusted hazard ratio [HR] = 1.16, 95% CI =
1.04Y1.31, p = .01) and a 24% increased rate of heart failure
(HR = 1.24, 95% CI = 1.07Y1.45, p = .006). The adjustment for
shorter baseline telomere length in the depressed patients did
not affect these associations (HR = 1.14, 95% CI = 1.01Y1.28,
p = .03 for death; HR = 1.23, 95% CI = 1.05Y1.44, p = .009 for
heart failure).
DISCUSSION
In a sample of 952 patients with stable CHD, we found that
major depression was associated with a 71% greater odds of
having short telomere length. The participants with major de-
pression had an average telomere length that was 97 base pairs
shorter than those without depression. Assuming an average
TABLE 3. Association Between Major Depressive Disorder
and Short Telomere Length (Analyzed as a Dichotomous Variable,
Quartile 1 Versus 4)
Adjusted for Odds Ratio (95% CI) p
Age and sex 1.73 (1.08Y2.79) .02
Age, sex, diabetes, BMI, and smoking 1.65 (1.03Y2.67) .04
Age, sex, diabetes, BMI, smoking,
LVEF, statin use, physical inactivity,
and antidepressant use
1.72 (1.02Y2.89) .04
Age, sex, diabetes, BMI, smoking,
LVEF, statin use, physical inactivity,
antidepressant use, and anxiety
1.71 (0.98Y2.98) .06
CI = conﬁdence interval; BMI = body mass index; LVEF = left ventricular
ejection fraction.
Figure 1. Proportion of participants who experienced telomere shortening,
maintenance, or lengthening, during the 5 years of follow-up ( p = .03 from
overall W2), unadjusted for age or baseline telomere length.
TABLE 4. Association Between Major Depressive Disorder and
Subsequent Shortening in Leukocyte Telomere Length (910% Decrease)
Adjusted for Odds Ratio (95% CI) p
Age, sex 0.66 (0.43Y1.00) .05
Age, sex, diabetes, BMI, smoking 0.67 (0.44Y1.01) .06
Age, sex, diabetes, BMI, smoking,
LVEF, statin use, physical inactivity,
and antidepressant use
0.63 (0.40Y0.99) .04
Age, sex, diabetes, BMI, smoking,
LVEF, statin us, physical inactivity,
antidepressant use, and anxiety
0.68 (0.42Y1.12) .13
Age, sex, diabetes, BMI, smoking,
LVEF, statin use, physical inactivity,
antidepressant use, anxiety, and
baseline telomere length
0.76 (0.40Y1.44) .40
CI = conﬁdence interval; BMI = body mass index; LVEF = left ventricular
ejection fraction.
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rate of loss of around 42 base pairs per year (13), this indicates
that their leukocytes had aged the equivalent of 2.3 additional
years, compared with patients without depression.
Depression and Baseline Telomere Length
Previous cross-sectional studies have found that psychoso-
cial factors are associated with shorter telomere length, but the
relation between depression and telomere length has not pre-
viously been evaluated in patients with CHD. Epel et al. (4)
demonstrated that the chronicity and perceived severity of
psychosocial stress was directly associated with accelerated
telomere shortening in middle-aged healthy women (n = 65).
Simon et al. (6) measured leukocyte telomere length in 44
individuals with chronic mood disorders and 44 nonpsychiatric
ill age-matched control subjects and found that telomere length
was signiﬁcantly shorter in those with mood disorders. Lung
et al. (5) found an association between depression and short
telomere length among 253 depressed patients compared with
411 community controls. Another study found that poor per-
ceived mental health, but not depressive symptoms, was asso-
ciated with shorter telomere length in 890 patients with
congestive heart failure (7). Our study adds to this growing
literature by demonstrating that depression is associated with
short telomere length in patients with CHD. In addition, our
ﬁndings demonstrate that, although associated with shorter
baseline telomere length, current depression does not predict
subsequent shortening.
Underlying Mechanisms
Further research is necessary to examine the mechanisms
underlying the association between depression and reduced
telomere length in CHD patients. Potential links between de-
pression and shortened telomere length could be oxidative
stress and inﬂammation (20). Previous studies have demon-
strated an association between depression and oxidative stress.
Depressed patients have increased levels of circulating oxida-
tive stress markers and decreased levels of antioxidant enzymes
(21Y23). In addition, some, but not all studies, have found that
depression is associated with increased levels of proinﬂamma-
tory cytokines (24,25). Both oxidative stress and proinﬂam-
matory cytokines have been found to inﬂuence telomere length.
Oxidative stress has a negative effect on telomere length, through
inhibition of telomerase activity (26) and direct erosion of GGG
triplets in telomeric DNA (27). Proinﬂammatory cytokines may
either decrease or increase telomerase activity (28Y30) and are
thought to lead to immune cell turnover, and thus decreased
telomere length through greater replicative history.
Depression and 5-Year Change in Telomere Length
Little is known concerning the dynamic regulation of telo-
mere length over time. Recently, it has become apparent that
telomeres may lengthen and shorten (13,31). In our sample, less
than half of the participants experienced telomere shortening,
and almost a quarter actually lengthened their telomeres during
the 5-year follow-up period. In this longitudinal study we ob-
served that MDD was associated with a 32% decreased odds
of shortening (i.e., greater odds of lengthening). However, short
baseline telomere length is by far the strongest predictor of
subsequent lengthening, and this association was not signiﬁcant
after further adjustment for shorter baseline telomere length
in depressed participants. Therefore, depression does not seem
to predict 5-year subsequent change in telomere length inde-
pendently. These ﬁndings are in concordance with the previ-
ous studies that found that telomere trajectory is powerfully
inﬂuenced by baseline telomere length and that both healthy
individuals and CHD patients with the longest telomeres expe-
rienced the greatest amount of shortening, whereas those with
shorter telomeres either maintained or increased in their length
(13,31,32).
An important regulator of this negative feedback is the
enzyme telomerase, which is a reverse transcriptase enzyme that
restores telomere length. Telomerase has been shown to act
preferentially on short telomeres in mice models and cell culture
systems (33Y36). Moreover, chronically stressed caregivers who
are also high in depressive symptoms have increased levels of
telomerase (37). Thus, it is possible that depression may have
contributed to shorter baseline telomeres, but over a follow-up
time of 5 years, the subsequent negative feedback from those
short telomeres may overwhelm any independent effect on tra-
jectory. Alternatively, the current ﬁndings are consistent with a
model in which depression is a consequence of short telomeres
or in which a shared (genetic) risk factor is responsible for both
depression and short telomere length at baseline.
TABLE 5. Five-Year Percent Change in Telomere Length (Analyzed as a Continuous Variable) by the Presence of Major Depressive Disorder
Among 608 Participants Who Provided Follow-Up DNA Samples
Adjusted for Current Depression (n = 127) No Current Depression (n = 481) p
Age and sex j0.6 (2.0) j5.2 (1.3) .03
Age, sex, diabetes, BMI, and smoking j1.9 (2.2) j6.1 (1.6) .05
Age, sex, diabetes, BMI, smoking, LVEF, statin use, physical inactivity,
and antidepressant use
j1.1 (2.2) j6.5 (1.9) .02
Age, sex, diabetes, BMI, smoking, LVEF, statin use, physical inactivity,
antidepressant use, and anxiety
j0.9 (2.4) j6.6 (1.9) .03
Age, sex, diabetes, BMI, smoking, LVEF, statin use, physical inactivity,
antidepressant use, anxiety, and baseline telomere length
j3.0 (1.7) j5.6 (1.3) .13
Data are presented as Mean (Standard Error of the Mean).
DNA = deoxyribonucleic acid; BMI = body mass index; LVEF = left ventricular ejection fraction.
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Depression and Mortality
Currently, a large body of literature has conﬁrmed that
depressive symptoms are associated with greater mortality
among patients with established CHD (8,11). A recent study
showed that shorter telomere length was associated with all-
cause mortality and heart failure in patients with stable CHD
(9). Because depression is associated with shorter telomere
length, this raises the question of whether accelerated cellular
aging is a mechanism that contributes to the excess morbidity
and mortality associated with depression (6,38). To our knowl-
edge, we are the ﬁrst study that evaluates whether shortened
telomere length may potentially underlie the relationship be-
tween depression and heart failure and mortality. The adjust-
ment for baseline telomere length in the depressed patients did
not affect the association between depression and prognosis.
Strengths and Limitations
Our study has several strengths, including repeated mea-
surements of telomere length; measurement of multiple poten-
tial confounding variables including BMI, LVEF, smoking, and
physical inactivity; and detailed assessments of depression.
However, some limitations of this study should be noted. First,
this study included stable CHD patients and mainly older men.
Thus, the results may not generalize to women or to healthy
or acute coronary syndrome populations. Second, we did not
measure the impact of telomerase activity on the prognostic
value of leukocyte telomere length. Third, telomere length
measurements were restricted to circulating leukocytes, do not
necessarily reﬂect telomere length in other cell compartments,
and do not inform about accelerated aging of any particular
immune cell subpopulation. Fourth, the association between
depression and shortened telomere length may have been the
result of greater cardiac disease severity in depressed patients,
although we attempted to address this possibility by carefully
measuring and adjusting for cardiovascular disease severity.
Fifth, the severity of depressive symptomswas relatively lowwith
an average PHQ score of 10.7 among depressed participants.
Finally, we did not assess the chronicity or duration of depres-
sion at the baseline examination nor did we account for con-
tinued depression or other psychiatric diagnoses at follow-up.
CONCLUSIONS
To our knowledge, this is the ﬁrst study to examine and
report an association between depression and telomere length in
patients with stable CHD. In summary, we found that patients
with current depression had a shorter telomere length at base-
line. However, current depression did not predict subsequent
change in telomere length. Future research is necessary to
elucidate the mechanism underlying the association between
depression and telomere length.
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